Drug Trial Radar · NCT01780506
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Last checked: Nov 19, 2026Latest source record: Nov 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
872
Actual
Start
Dec 26, 2012
Primary completion
Aug 26, 2014
Study completion Sep 6, 2017
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jan 31, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
Conditions
- HIV
- HIV Infections
Interventions
E/C/F/TAFDrug
150/150/200/10 mg FDC tablet administered orally once daily
E/C/F/TDFDrug
150/150/200/300 mg FDC tablet administered orally once daily
E/C/F/TDF PlaceboDrug
Tablet administered orally once daily
E/C/F/TAF PlaceboDrug
Tablet administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48
Locations
117 sites in 12 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Spectrum Medical Group
Phoenix, Arizona
Kaiser Permanente Los Angeles
Los Angeles, California
University of California, Los Angeles
Los Angeles, California
Peter J. Ruane, MD, Inc.
Los Angeles, California
Anthony Mills MD Inc
Los Angeles, California
East Bay AIDS Center
Oakland, California
Kaiser Permanente - Sacramento
Sacramento, California
La Playa Medical Group and Clinical Research
San Diego, California
University of California, San Diego
San Diego, California
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California
Apex Research, LLC
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
Dupont Circle Physicians Group, P.C.
Washington D.C., District of Columbia
Whitman Walker Clinic
Washington D.C., District of Columbia
Capital Medical Associates, P.C.
Washington D.C., District of Columbia
Gary Richmond, MD, PA, Inc.
Fort Lauderdale, Florida
Midway Immunology & Research Center, LLC
Ft. Pierce, Florida
The Kinder Medical Group
Miami, Florida
AIDS Healthcare Foundation
Miami Beach, Florida
Orlando Immunology Center
Orlando, Florida
IDOCF/ValuHealthMD, LLC
Orlando, Florida
Infectious Diseases Associates
Pensacola, Florida
The University of South Florida
Tampa, Florida
Infectious Disease Research Institute Inc.
Tampa, Florida
St. Joseph's Comprenhensive Research Inisitute
Tampa, Florida
AIDS Research and Treatment Center of the Treasure Coast
Vero Beach, Florida
AIDS Research Consortium of Atlanta
Atlanta, Georgia
Emory University
Atlanta, Georgia
Atlanta ID Group, PC
Atlanta, Georgia
Infectious Disease Specialist of Atlanta
Decatur, Georgia
Mercer University School of Medicine
Macon, Georgia
University of Hawaii - Hawaii Center for AIDS
Honolulu, Hawaii
Northwestern University
Chicago, Illinois
Ruth M. Rothstein CORE Center
Chicago, Illinois
Howard Brown Health Center
Chicago, Illinois
Institute of Human Virology, University of Maryland
Baltimore, Maryland
Community Research Initative
Boston, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts
Metrowest Medical Center
Framingham, Massachusetts
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.